alterations,drugs,approvedIndications,level,fdaLevel,levelAssociatedCancerType,levelExcludedCancerTypes,pmids,abstracts,description
['Oncogenic Mutations'],"[{'ncitCode': 'C165776', 'drugName': 'Revumenib'}]",[],LEVEL_3A,LEVEL_Fda3,"{'id': 527, 'code': 'AML', 'color': 'LightSalmon', 'name': 'Acute Myeloid Leukemia', 'mainType': {'id': None, 'name': 'Leukemia', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'MNM', 'level': 3, 'tumorForm': 'LIQUID'}",[],['31855575'],"[{'link': 'https://ashpublications.org/blood/article/138/Supplement%201/699/479484/Safety-and-Efficacy-of-Menin-Inhibition-in', 'abstract': 'Stein et al. Abstract# 699, ASH 2021.'}]","Revumenib is a small inhibitor of menin, a regulator of the leukemogenic HOX and MEIS1 genes. In the Phase I AUGMENT 101 study of revumenib in MLL-rearranged and NPM1-mutant acute leukemia, of the patients with NPM1 mutations (n=10), the composite complete response was 30% (n=3/10) (Abstract: Stein et al. Abstract# 699, ASH 2021. https://ashpublications.org/blood/article/138/Supplement%201/699/479484/Safety-and-Efficacy-of-Menin-Inhibition-in). Preclinical studies in acute leukemia cells with KMT2A translocations or NPM1 mutations have demonstrated that menin inhibition induces differentiation and inhibits proliferation (PMID: 31855575)."
